New light commercial vehicle (LCV) registrations fell by 12.1% to 156,048 units in the first half of 2025, according to the ...

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Demand for battery-electric vans surged 53 per cent in the UK in the first half of 2025. In June alone, registrations even ...

New diesel van registrations shrank by 12.1% to 156,048 units in the first half of 2025, whilst electric van demand rose by ...

The new car market recorded its second consecutive month of growth in June, with registrations rising 6.7% year-on-year ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

The UK's new van market shrank every month during the first half of 2025, according to the latest figures. The Society of Motor Manufacturers and Traders (SMMT) said LCV registrations declined by 12.1 ...

UK van sales dropped 12.1% in H1 2025, with tax changes and weak economic confidence stalling fleet renewal and slowing the ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Despite the progress, BEV uptake remains behind the government’s 28% target for 2025. In the first half of the year, BEVs ...

Sales remained below pre-COVID levels, but it was the best June since 2019, the Society of Motor Manufacturers and Traders ...